Imbria Pharmaceuticals has randomised the first participant in FORTITUDE HCM, a Phase IIb trial of ninerafaxstat in ...

Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites ...

Record quarterly revenue of $230.6 million, up 20% QoQ and 104% YoY Strong Q3 revenue growth driven by new AI platform ramps featuring multiple product familiesScorpio fabric switch design wins expand ...

Eyewitnesses reported Burmese soldiers in the three battalions are forcing local civilians from Mongkoe and Hpawng Seng to ...